Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Novartis Acquires SanReno Therapeutics, a Shanghai Company with Two IgAN Candidates

publication date: Jan 5, 2024

Novartis acquired the 50% of Shanghai’s SanReno Therapeutics it didn’t already own from the consortium of investors who helped to found the company in 2021. SanReno, a company developing two late-stage therapies for Immunoglobulin A Nephropathy (IgAN), was formed by Seattle’s Chinook Therapeutics in late 2021 to bring its kidney disease drug candidates to China and Singapore. Chinook, which owned 50% of SanReno, was acquired by Novartis in a $3.5 billion agreement in June of last year. The remaining 50% belonged to SanReno’s founding investors: Pivotal bioVenture Partners China, Frazier Life Sciences, Samsara BioCapital, and Versant Ventures, who capitalized SanReno with an original $40 million round. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here